In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Invivyd (IVVD – Research Report), with a price target of $5.00. The company’s shares opened today at $1.37.
According to TipRanks, Trucchio is an analyst with an average return of -16.7% and a 31.34% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Oncolytics Biotech, and COMPASS Pathways.
Invivyd has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.90 and a one-year low of $0.98. Currently, Invivyd has an average volume of 392.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
Read More on IVVD:
- Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
- Invivyd announces alignment with FDA on pathway to potential VYD222 EUA
- Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
- Invivyd announces initial data from ongoing Phase 1 trial of VYD222
- Invivyd to Participate at the Jefferies Healthcare Conference
